12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vedolizumab regulatory update

Takeda submitted an MAA to EMA for vedolizumab to treat moderately to severely active ulcerative colitis (UC)...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >